NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis → I tried to warn you (From Porter & Company) (Ad) Free VSTM Stock Alerts $11.80 -0.02 (-0.17%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$11.68▼$12.1050-Day Range$10.50▼$14.0752-Week Range$4.20▼$15.18Volume98,806 shsAverage Volume171,257 shsMarket Capitalization$298.48 millionP/E RatioN/ADividend YieldN/APrice Target$28.79 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Verastem alerts: Email Address Verastem MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside143.9% Upside$28.79 Price TargetShort InterestBearish3.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 4 Articles This WeekInsider TradingSelling Shares$107,388 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.31) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.27 out of 5 starsMedical Sector633rd out of 940 stocksPharmaceutical Preparations Industry298th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.79, Verastem has a forecasted upside of 143.9% from its current price of $11.80.Amount of Analyst CoverageVerastem has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.78% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Verastem has recently increased by 1.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 2.4 News and Social Media Coverage News SentimentVerastem has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Verastem this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for VSTM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $107,388.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($4.31) to ($2.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -2.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyI tried to warn you America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About Verastem Stock (NASDAQ:VSTM)Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More VSTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VSTM Stock News HeadlinesMarch 27, 2024 | markets.businessinsider.comVerastem’s Strategic Advancements and Financial Stability Underscore Buy RatingMarch 27, 2024 | americanbankingnews.comVerastem (NASDAQ:VSTM) Stock Crosses Above 200-Day Moving Average of $9.30March 30, 2024 | Porter & Company (Ad)I tried to warn you America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.March 22, 2024 | investing.comVerastem director sells over $8,500 in company stockMarch 20, 2024 | americanbankingnews.comVerastem's (VSTM) Buy Rating Reiterated at HC WainwrightMarch 20, 2024 | finance.yahoo.comVSTM Apr 2024 11.000 callMarch 19, 2024 | markets.businessinsider.comVerastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term LossesMarch 18, 2024 | businesswire.comGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerMarch 30, 2024 | Porter & Company (Ad)I tried to warn you America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.March 16, 2024 | finance.yahoo.comVSTM Apr 2024 14.000 callMarch 14, 2024 | benzinga.comRecap: Verastem Q4 EarningsMarch 14, 2024 | investorplace.comVSTM Stock Earnings: Verastem Misses EPS for Q4 2023March 14, 2024 | businesswire.comVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesMarch 11, 2024 | finance.yahoo.comVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsMarch 11, 2024 | businesswire.comVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsMarch 10, 2024 | finance.yahoo.comVSTM Mar 2024 2.000 putMarch 6, 2024 | markets.businessinsider.comVerastem Oncology Granted FDA Orphan Drug Designation For Avutometinib In Ovarian CancerMarch 6, 2024 | msn.comVerastem gets FDA orphan drug status for low-grade ovarian cancer therapyMarch 5, 2024 | businesswire.comVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian CancerMarch 5, 2024 | businesswire.comVerastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024February 23, 2024 | benzinga.comVerastem Stock (NASDAQ:VSTM), Short Interest ReportFebruary 15, 2024 | finance.yahoo.comAndreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem IncFebruary 7, 2024 | finance.yahoo.comDirector Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)February 7, 2024 | seekingalpha.comVerastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of DefactinibJanuary 30, 2024 | markets.businessinsider.comBuy Rating on Verastem: Strategic Execution and Promising Drug Pipeline Signal Market OpportunityJanuary 29, 2024 | finance.yahoo.comVerastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven CancersJanuary 20, 2024 | msn.comVerastem Shareholders Approve Executive Option Exchange PlanSee More Headlines Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/29/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees73Year FoundedN/APrice Target and Rating Average Stock Price Target$28.79 High Stock Price Target$36.00 Low Stock Price Target$17.50 Potential Upside/Downside+143.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.1004) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.00% Return on Assets-54.73% Debt Debt-to-Equity Ratio0.70 Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$2.60 million Price / Sales114.82 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book5.20Miscellaneous Outstanding Shares25,300,000Free Float24,561,000Market Cap$298.54 million OptionableOptionable Beta0.49 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel W. Paterson (Age 63)President, CEO & Director Comp: $697.98kMr. Daniel Calkins (Age 36)CFO, Head of Investor Relations, Principal Accounting & Financial Officer Comp: $1.42MMr. Richard H. Aldrich M.B.A. (Age 70)Founder and Consultant Comp: $38.39kDr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Piyush B. Gupta Ph.D.Co-FounderDr. Michelle Dipp M.D. (Age 48)Ph.D., Co-Founder Mr. Robert Pintar M.B.A.Senior Vice President of Technical OperationsDr. Jonathan Pachter Ph.D. (Age 66)Chief Scientific Officer Comp: $238.18kMr. Nate SanburnSenior Vice President of Corporate Development & External EngagementDr. Hagop Youssoufian M.D. (Age 67)M.Sc., Ph.D., Head of Medical Strategy More ExecutivesKey CompetitorsXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLEpizymeNASDAQ:EPZMVanda PharmaceuticalsNASDAQ:VNDAMerrimack PharmaceuticalsNASDAQ:MACKView All CompetitorsInsiders & InstitutionsDaniel CalkinsSold 25 sharesTotal: $300.50 ($12.02/share)Daniel CalkinsSold 55 sharesTotal: $608.85 ($11.07/share)Dan PatersonSold 244 sharesTotal: $2,613.24 ($10.71/share)Robert E GagnonSold 283 sharesTotal: $3,030.93 ($10.71/share)Goldman Sachs Group Inc.Sold 15,278 shares on 3/1/2024Ownership: 0.086%View All Insider TransactionsView All Institutional Transactions VSTM Stock Analysis - Frequently Asked Questions Should I buy or sell Verastem stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks. What is Verastem's stock price target for 2024? 7 Wall Street research analysts have issued 12 month price targets for Verastem's shares. Their VSTM share price targets range from $17.50 to $36.00. On average, they expect the company's stock price to reach $28.79 in the next twelve months. This suggests a possible upside of 143.9% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. How have VSTM shares performed in 2024? Verastem's stock was trading at $8.14 at the start of the year. Since then, VSTM stock has increased by 45.0% and is now trading at $11.80. View the best growth stocks for 2024 here. When is Verastem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VSTM earnings forecast. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.60. When did Verastem's stock split? Shares of Verastem reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX). Who are Verastem's major shareholders? Verastem's stock is owned by many different institutional and retail investors. Top institutional shareholders include Royal Bank of Canada (0.22%), Dimensional Fund Advisors LP (0.16%), Goldman Sachs Group Inc. (0.09%), Goldman Sachs Group Inc. (0.09%), Stifel Financial Corp (0.07%) and International Assets Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VSTM) was last updated on 3/30/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsI tried to warn you Porter & Company“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsThe 3rd Revolution in WarfareWeiss RatingsFed launches fourth dollar overhaulStansberry ResearchIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill PublishingWARNING - this content may be disturbingParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.